Anson Funds Management’s Avita Medical RCEL Stock Holding History

Anson Funds Management’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,954	Closed	-$296K	–	295
2020 Q4	$296K	Buy	+15,954	New	+$350K	0.06%	138

Other funds holding RCEL

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Anson Funds Management's RCEL Position: Q1 2021 in Review

Anson Funds Management sold out of Avita Medical (RCEL) in Q1 2021, closing a stake of 15,954 shares — an estimated $296K sold.

Anson Funds Management first reported a position in RCEL in Q4 2020 and held it in 1 quarter. The position peaked at $296K in Q4 2020. 61 funds tracked by Wall St. Rank hold RCEL as of Q1 2021.

Anson Funds Management reported no remaining Avita Medical position as of Q1 2021 after selling out during the quarter.
Anson Funds Management sold 15,954 Avita Medical shares in Q1 2021, an estimated $296K.
Anson Funds Management first reported a position in Avita Medical in Q4 2020 and held it in 1 quarter.
Anson Funds Management's Avita Medical position peaked at $296K in Q4 2020.
61 funds tracked by Wall St. Rank held Avita Medical as of Q1 2021.

Based on Anson Funds Management's 13F filing for Q1 2021, filed 14 May 2021.